Table 3.
Effects of treatment with nucleos(t)ide analogs in patients with decompensated cirrhosis
| Ref. | Nucleos(t)ide | Patient number | Treatment duration | Improvement ratio of Child-Pugh score | Cumulative survival rate3 |
| Villeneuve et al[18] | LAM (100 mg or 150 mg) | 35 (CPB: 10, CPC: 25) | Mean: 19 mo | 62.9% (22/35)1 | 1 yr: 78%4 |
| 2 yr: 63%4 | |||||
| Kapoor et al[19] | LAM (150 mg) | 18 (CPB: 14, CPC: 4) | Mean: 17.9 mo (range: 9-31 mo) | CPB to CPA: 50% (4/14) | No deaths attributed to liver disease |
| CBC to CPB: 50% (2/4) | |||||
| Yao et al[20] | LAM (150 mg) | 13 (CPB: 0, CPC: 13) | Mean: 17.5 mo (range: 3-39 mo) | 69% (9/13)2 | Not described |
| Hann et al[22] | LAM (100 mg) | 75 (CPA: 4, CPB: 28, CPB: 43) | Mean: 12.7 mo (range: 0.5-33 mo) | 31% (23/75)1 | Not described |
| Tseng et al[23] | LAM (100 mg) | 30 (CPB: 16, CPC: 14) | Mean: 39.7 mo (range: 3-128 mo) | CPB to CPA: 62.5% (10/16) | 1 yr 70%4 |
| CBC to CPB: 35.7% (5/14) | 2 yr 66%4 | ||||
| 3 yr 55%4 | |||||
| 5 yr 55%4 | |||||
| Bae et al[24] | LAM (100 mg) | 17 (CPB: 12, CPC: 5) | Mean: 28 mo (range: 14-42 mo) | CPB to CPA: 83% (10/12) | Not described |
| CBC to CPB (1/5) or CPA (3/5): 80% (4/5) | |||||
| Shim et al[25] | ETV (0.5 mg) | 55 (mean CP score 8.1 ± 1.7) | 12 mo | 49% (27/55)1 | 12 mo: 87.1% |
| 24 mo: 83.0% | |||||
| Hyun et al[26] | LAM (100 mg) | 86 (CPB: 45, CPC: 41) | Mean: 2 yr | Mean Child-Pugh score | 1 yr |
| ETV (0.5 mg) | Baseline | LAM: 92.4% | |||
| LAM: 9.5, ETV: 9.6 | ETV: 90.7% | ||||
| 12 mo | 3 yr | ||||
| LAM: 6.7, ETV: 6.6 | LAM: 86%4 | ||||
| ETV: 76%4 | |||||
| Liaw et al[27] | TDF (300 mg)/FTC (200 mg) + TDV (300 mg)/ETV (0.5 mg or 1 mg) | 112 (median CP score: 7, range: 6-9) | 48 wk | TDF: 25.9% (7/27)1 | Not described |
| FTC/TDF: 48.0% (12/25)1 | |||||
| ETV: 41.7% (5/12)1 | |||||
| Chan et al[29] | LAM (100 mg), TdT (600 mg) | 228 (CPS < 7: 18, CPS 7-9: 155, CPS 9 <: 55) | 52-104 wk | 52 wk | 52 wk |
| LAM: 38.6% (44/114), TdT: 31.6% (36/114)1 | LAM: 88%, TdT: 94% | ||||
| 104 wk | 104 wk | ||||
| LAM: 40.4% (46/114 ), TdT: 38.6% (44/114)1 | LAM: 79%, TdT: 87% |
1
Improvement of Child-Pugh score was defined as a decrease in the CPS greater than or equal to 2-points;
2
Improvement of Child-Pugh score was defined as a decrease in the CPS greater than or equal to 3-points;
3
Cumulative survival rates calculated by Kaplan-Meier method;
4
Approximate value from the published graph. LAM: Lamibudine; ETV: Entecavir; TDF: Tenofovir; FTC: Emtricitabine; TdT: Telbivudine; CPB: Child-Pugh class B; CBC: Child-Pugh class C; CPS: Child Pugh score; CPA: Child-Pugh class A.